http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102164909-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-443
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-02
filingDate 2009-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad8d1f89771bba879e925b293eca621a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4580a85b519a7072160f44c28af57eba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdac8553efa4f5ea582d79afc6033d2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc1f68d9c32455def0991961b3e412c5
publicationDate 2011-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-102164909-A
titleOfInvention Pyridine or pyrazine derivatives for the treatment of HCV
abstract The present invention discloses a compound of formula I wherein R 1 , R 2a , R 2b , R 2c , R 3 , Y and p are as defined herein and C2-C3 are single or double bonds, which is polymerized by hepatitis C virus NS5b Enzyme inhibitors. The invention also discloses compositions and methods for treating HCV infection and inhibiting HCV replication.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109311880-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109311880-A
priorityDate 2008-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0185172-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008082484-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006040927-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420430956
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467575277
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467934456
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467575292
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID424928828
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID86638342
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22940028
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466504217
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468395607

Total number of triples: 44.